MSACL 2018 US Abstract


Notice: Undefined variable: keynote in /home/msacl0017/public_html/view_abstract/MSACL_2018_US.php on line 84

Topic: Practical Training

Design a Customized and Effective Quality Assurance Program for Your Laboratory : Part 2

Kara Lynch (Presenter)
University of California San Francisco

Bio: Dr. Kara Lynch is an Associate Professor of Laboratory Medicine at the University of California San Francisco and the Co-Director of the Core Laboratory (Clinical Chemistry and Toxicology) at Zuckerberg San Francisco General Hospital and Trauma Center. She received her PhD in Biochemistry from the University of Wisconsin and did a post-doctoral fellowship in Clinical Chemistry in the COMACC approved training program at UCSF. Her primary area of research is in Clinical Toxicology. Her laboratory conducts studies aimed at identifying and quantifying toxins, drugs of abuse and adulterants in biological specimens using mass spectrometry and correlating the findings with clinical pathologies.

Authorship: Kara Lynch (1) and Lorin Bachmann (2)
(1) University of California San Francisco and (2) Virginia Commonwealth University Medical Center

Short Abstract

Current laboratory practice guidelines outline metrics that should be monitored in LC-MS/MS QA programs; however, few resources provide specific steps on how to design a value-added QA program. In this session, practical examples and step-by-step instructions will be provided to demonstrate how to effectively select QA parameters, establish QA acceptability criteria, monitor QA data and utilize QA metrics to critically assess test performance. The first half will cover how meta-data can be used to define QA goals and catch problems early. The last half will demonstrate how to establish custom QA metric acceptability criteria using a statistical data-driven approach.

Long Abstract

Introduction

Methods

Results

Conclusions & Discussion


References & Acknowledgements:


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no